Galantos Pharma develops therapeutics for neurodegenerative diseases with a primary focus on Alzheimer’s dementia. Its lead compound is Memogain®, which the company plans to advance into clinical testing. The company raised €4.4m in a Series C financing to support that progression and the development of additional neuroprotective AD compounds. Investors in the round include VRP, KfW, FIB, WFT and HTGF, and it also received public funds from the BMBF. The financing will be used specifically to bring Memogain® into the clinic and to develop novel Alzheimer’s disease compounds. Galantos is based in Mainz, Germany.

Total raised

$6M

Funding rounds

1

Latest round

Series C

Latest activity

May 2010